Use of nonionic block copolymers in vaccines and therapeutics

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 15, Issue 2, 1998, Pages 89-142

  Newman, Mark J ^a   Actor, Jeffrey K ^b   Balusubramanian, Mannersamy ^c   Jagannath, Chinnaswamy ^d  

^a Vaxcel Inc   (United States)

^b Vetlife Inc   (United States)

^c CytRx Corporation   (United States)

^d ProCeutics Corporation   (United States)

Author keywords

Adjuvant; Antibiotic; Nonionic block copolymer; Poloxamer; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; COPOLYMER; VACCINE;

ANTIGEN RECOGNITION; DRUG FORMULATION; DRUG SYNTHESIS; DRUG USE; HUMAN; HYDROPHOBICITY; REVIEW; VACCINATION;

EID: 0031966111     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v15.i2.10     Document Type: Review

References (119)

1. Schmolka, I. R., Polyalkylens oxide block copolymers, in Nonionic Surfactants, Schick, M. J., Ed., New York: Marcel Dekker, 1966, 300.
2. Lundsted, L. G. and Schmolka, I. R., The synthesis and properties of block copolymer surfactants, in Block and Graft Copolymerization, Ceresa, R. J., Ed., London: John Wiley and Sons, 1976, 1.
3. Schmolka, I. R., Poloxamers in the pharmaceutical industry, in Polymers for Controlled Drug Delivery, Tarcha, P. J., Ed., Boca Raton, FL: CRC Press, 1991, 189.
4. Rieger, M. M., Surfactants, in Pharmaceutical Dosage Forms: Disperse Systems, Lieberman, H. A., Rieger, M. M., and Banker, G. S., Eds., New York: Marcel Dekker, 1988, 349.
5. St. Pierre, L. E., Polymers from 1,2 epoxides: I. Chemistry, in Polyethers, Gaylord, N. G. Ed., New York: Interscience Publishers, 1963, 83.
6. Kastens, A. S., Polymers from 1,2 epoxides: II. Applications and technologies, in Polyethers, Gaylord, N. G., Ed., New York: Interscience Publishers, 1963, 169.
7. Schmitt, T. M., Analysis of Surfactants, New York: Marcel Dekker, 1992.
8. Lundsted, L. G. and Schmolka, I. R., The applications of block copolymer polyol surfactants, in Block and Graft Copolymerization, Ceresa, R.J., Ed., London: Wiley, 1976, 113.
9. Whitmarsh, R. H., Synthesis and chemical modification of polyoxylalkylene block copolymers, in Nonionic Surfactants, Nace, V. M., Ed., New York: Marcel Dekker, 1996, 1.
10. Audibert, F., Chedid, L., Lefrancier, P., and Choay, J., Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components, Cell. Immunol., 21, 243, 1976.
11. Damais, C., Parant, M., Chedid, L., Lefrancier, P., and Choay, J., In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice, Cell. Immunol., 35, 173, 1978.
12. Tanaka, A., Nagao, S., Nagao, R., Kotani, S., Shiba, T., and Kusumoto, S., Stimulation of the reticuloendothelial system of mice by muramyl dipeptide, Infect. Immun., 24, 302, 1976.
13. Gery, I., Kruger, J., and Spiesel, S. Z., Stimulation of B-lymphocytes by endotoxin: Reactions of thymus-deprived mice and karyotypic analysis of dividing cell in mice bearing T6T6 thymus grafts, J. Immunol., 108, 1088, 1972.
14. Johnson, A. G. and Tomai, M. A., A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A.,Adv. Exp. Med. Biol. 256, 567, 1990.
15. Tomai, M. A. and Johnson, A. G., T cell and interferon-gamma involvement in the adjuvant action of detoxified endotoxin, J. Biol. Response Modif., 8, 625, 1989.
16. Arend, W. P. and Massoni, R. J., Characteristics of bacterial lipopolysaccharide induction of interleukin 1 synthesis and secretion by human monocytes, Clin. Exp. Immunol., 64, 656, 1986.
17. Flebbe, L. M. and Braley-Mullen, H., Immunopotentiating effects of the adjuvants SGP and Quil A. I., Antibody responses to T dependent and T independent antigens, Cell. Immunol., 99, 119, 1986.
18. Flebbe, L. M. and Braley-Mullen, H., Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations, Cell. Immunol., 99, 128, 1986.
19. Kensil, C. R., Patel, U., Lennick, M., and Marciani, D., Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex, J. Immunol., 146, 431, 1991.
20. Wu, J.-Y., Gardner, B. H., Kushner, N. N., Pozzi, L.-A. M., Kensil, C. R., Cloutier, P. A., Coughlin, R. T., and Newman, M. J., Accessory cell requirements for saponin adjuvant-induced class IMHC antigen-restricted cytotoxic T-lymphocytes, Cell. Immunol., 154, 393, 1994.
21. Heath, A. W. and Playfair, J. H. L., Cytokines as immunological adjuvants, Vaccine, 10, 427, 1992.
22. Tagliabue, A. and Boraschi, D., Cytokines as vaccine adjuvants: Interleukin 1 and its synthetic peptide 163-171, Vaccine, 11, 594, 1993.
23. Schijns, V. E. C. J., Claassen, I. J. T. M., Vermeulen, A. A., Horzinek, M. C., and Osterhaus, A. D. M. E., Modulation of antiviral immune responses by exogenous Cytokines: Effects of tumour necrosis factor-α, interleukin-1α, interleukin-2, and interferon-gamma on the immunogenicity of an inactivated rabies vaccine, J. Gen. Virol., 75, 55, 1994.
24. Alfonso, L. C. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G., and Scott, P., The adjuvant effect of interleukin-12 in a vaccine against Leishmania major, Science, 263, 235, 1994.
25. Nash, A. D., Lofthouse, S. A., Barcham, G. J., Jacobs, H. J., Ashman, K., Meeusen, E. N. T., Brandon, M. R., and Andrews, A. E., Recombinant cytokines as immunological adjuvants, Immunol. Cell Biol., 71, 367, 1993.
26. Nohria, A. and Rubin, R. H., Cytokines as potential vaccine adjuvants, Biotherapy, 7, 261, 1994.
27. Gupta, R. K., Rost, B. E., Relyveld, E., and Siber, G. R., Adjuvant properties of aluminum and calcium compounds, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M., F. and Newman, M., J. Eds., New York: Plenum Press, 1995, 229.
28. Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., and Van Nest, G., MF59: Design and evaluation of a safe and potent adjuvant for human vaccines, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1995, 277.
29. McKercher, P. D., Oil adjuvants: Their use in veterinary biologics, in Advances in Carriers and Adjuvants of Veterinary Biologies, Nervig, R. M., Gough, P. M., Kaeberle, M. L., and Whetstone, C. A., Eds., Ames, IA: Iowa State University Press, 1986, 115.
30. Woodard, L. F. and Jasman, R. L., Stable oil-in-water emulsions: Preparation and use as vaccine vehicles for lipophilic adjuvants, Vaccine, 3, 137, 1985.
31. Hilleman, M. R., Critical appraisal of emulsified oil adjuvants applied to viral vaccines, Prog. Med. Virol., 8, 131, 1966.
32. Allison, A. C. and Gregoriadis, G., Liposomes as immunological adjuvants, Nature, 252, 252, 1974.
33. Gregoriadis, G., Davis, D., and Davies, A., Liposomes as immunological adjuvants: Antigen incorporation studies, Vaccine, 5, 145, 1987.
34. Gluck, R., Liposomal presentation of antigens for human vaccines, in Vaccine Design: The Subunit and Adjuvant Approach Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1995, 325.
35. Cleland, J. L., Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1995, 439.
36. Eldridge, J. H., Staas, J. K., Meulbroek, J. A., McGhee, J. R., Tice, T. R., and Giller, R. M., Biodegradable microspheres as a vaccine delivery, Mol. Immunol., 28, 287, 1993.
37. Allison, A. C. and Byars, N. E., Syntex adjuvant formulation. Res. Immunol., 143, 519, 1992.
38. Allison, A. C. and Byars, N. E., Immunological adjuvants, Adv. Exp. Med. Biol., 327, 133, 1992.
39. Waksman, B., Adjuvants and immune regulation by lymphoid cells, Springer Semin. Immunopathol., 23, 5, 1979.
40. Jolles, P. and Paraf, A., Chemical and biological basis of adjuvants, in Molecular Biology and Biophysics, Kleinzeller, A., Springer, G., and Wittmann, H., Eds., New York: Springer-Verlag, 1973, 1.
41. Gall, D., Observations of the properties of adjuvants, in Symposia Series in Immunological Standardization, Regamey, R., Hennessen, W., and Ungar, J., Eds., New York: Karger, 1967, 39.
42. Hunter, R. L., Strickland, F., and Kezdy, F., Studies on the adjuvant activity of nonionic block polymer surfactants, I. The role of hydrophile-lipophile balance, J. Immunol., 127, 1244, 1981.
43. Howerton, D. A., Hunter, R. L., Ziegler, H. K., and Check, I. J., The induction of macrophage Ia expression in vivo by synthetic copolymer L81, J. Immunol., 144, 1578, 1990.
44. Hunter, R. L. and Bennett, B., The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblocks and octablock copolymers, J. Immunol., 133, 3167, 1984.
45. Hunter, R. L. and Bennett, B., The adjuvant activity of nonionic block polymer surfactants, III. Characterization of selected biologically active surfaces, Scand. J. Immunol., 23, 287, 1986.
46. Bennett, B., Check, I. J., Olsen, M. R., and Hunter, R. L., A comparison of commercially available adjuvants for use in research, J. Immunol. Methods, 153, 31, 1992.
47. Kast, W. M., Brandt, R. M. P., and Melief, C. J. M., Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination, Eur. J. Immunol., 23, 1189, 1993.
48. Ke, Y., Li, Y., and Kapp, J. A., Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses, Eur. J. Immunol., 25, 549, 1995.
49. Rousset, F., Peyrol, S., Garcia, E., Vezzio, N., Andujar, M., Grimaud, J.-A., and Banchereau, J., Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4, Int. Immunol., 7, 1243, 1995.
50. Claassen, E., De Leeuw, W., De Greeve, P., Hendriksen, C., and Boersma, W., Freund's complete adjuvant: An effective but disagreeable formula, Res. Immunol., 143, 478, 1992.
51. Hilleman, M. R., Woohour, A., Friedman, A., Weibel, R. E., and Stokes, J., The clinical application of adjuvant 65, Ann. Allergy, 30, 152, 1972.
52. Triozzi, P. L., Gochnour, D., Martin, E. W., Aldrich, W., Powell, J., Kim, J. A., Young, D. C., and Lombardi, J., Clinical and immunologic effects of a synthetic-human chorionic gonadotropin vaccine, Int. J. Cancer, 5, 1447, 1994.
53. Melief, C. J. M., Offringa, R., Toes, R. E. M., and Kast, W. M., Peptide-based cancer vaccines, Curr. Opin. Immunol., 8, 651, 1996.
54. Van den Eynde, B. and Brichard, V. G., New tumor antigens recognized by T cells, Curr. Opin. Immunol., 7, 674, 1995.
55. Cells, E., Fikes, J., Wentworth, P., Sidney, J., Southwood, S., Maewal, A., Del Guercio, M.-F., Sette, A., and Livingston, B., Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles, Mol. Immunol., 31, 1423, 1994.
56. Lidgate, D. M. and Byars, N. E., Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1995, 313.
57. Vogel, F. R. and Powell, M. F., A compendium of vaccine adjuvants and excipients, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1995, 141.
58. Raychaudhuri, S., Tonks, M., Carbone, F., Ryskamp, T., Morrow, W. J. W., and Hanna, N., Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo, Proc. Natl. Acad. Sci., 89, 8308, 1992.
59. Allison, A. C. and Byars, N. E., An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell mediated immunity, J. Immunol. Methods, 95, 157, 1986.
60. Byars, N. E., Fraser-Smith, E. B., Pecyk, R. A., Welch, M., Nakano, G., Burke, R. L., Hayward, A. R., and Allison, A. C., Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection, Vaccine, 12, 200, 1994.
61. Issel, C. J., Horohov, D. W., Lea, D. F., Adams, W. V., Jr., Hagius, S. D., McManus, J. M., Allison, A. C., and Montelaro, R. C., Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus, J. Virol., 66, 3398, 1992.
62. Montelaro, R. C., Grund, C., Raabe, M., Woodson, B., Cook, R. F., Cook, S., and Issel, C. J., Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines, AIDS Res. Hum. Retroviruses, 12, 413, 1996.
63. Murphey-Corb, M., Martin, L. N., Davison-Fairburn, B., Montelaro, R. C., Miller, M. A., West, M., Ohkawa, S., Baskin, G. B., Zhang, J.-Y., Allison, A. C., and Eppstein, D. A., A formalin-inactivated whole SIV vaccine confers protection in macaques, Science, 246, 1293, 1989.
64. Fenton, R. G., Taub, D. D., Kwak, L. W., Smith, M. R., and Longo, D. L., Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes, J. Nat. Cancer Inst., 85, 1294, 1993.
65. Keitel, W., Couch, R., Bond, N., Adair, S., Van Nest, G., and Dekker, C., Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant, Vaccine, 11, 909, 1993.
66. Hunter, R. L., Olsen, M. R., and Bennett, B., Copolymer adjuvants and Titermax, in The Theory and Practical Application of Adjuvants, Stewart-Tull, D. E. S., Ed., New York: Wiley, 1995, 51.
67. Kendal, A. P. and Dowdle, W. R., Influenza Virus, in Manual of Clinical Laboratory Immunology, Rose, N. R., Friedman, H., and Fahey, J. L., Eds., Washington, DC: American Society for Microbiology, 1986, 515.
68. Newman, M. J., Todd, C. W., Lee, E. M., Balusubramanian, M., Didier, P. J., and Katz, J. M., Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly, Mech. Ageing Dev., 93, 189, 1997.
69. Scott, P., Pearce, E., Cheever, A. W., Coffman, R. L., and Sher, A., Role of cytokines and CD4+ T-cell subsets in the regulation of parasitic immunity and disease, Immunol. Rev., 112, 161, 1989.
70. Seder, R. A. and Paul, W. E., Acquisition of lymphokine-producing phenotype by CD4+ T cells, Annu. Rev. Immunol., 12, 635, 1994.
71. Manetti, R., Parronchi, P., Guidizi, M. G., Piccinni, M.-P., Maggi, E., Trinchieri, G., and Romagnani, S., Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells, J. Exp. Med., 177, 1199, 1993.
72. Seder, R. A., Gazzinelli, R. T., Sher, A., and Paul, W. E., Interleukin-12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming, Proc. Natl. Acad. Sci. USA, 90, 10188, 1993.
73. Swain, S. L., Weinberg, A. D., English, M., and Huston, G., IL-4 directs the development of Th2-like helper effectors, J. Immunol., 145, 3796, 1990.
74. Kensil, C. R., Wu, J. Y., and Soltysik, S., Structural and immunological characterization of the vaccine adjuvant QS-21, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1996, 525.
75. O'Boyle, K. P., Zamore, R., Adluri, S., Cohen, A., Kemeny, N., Welt, S., Lloyd, K. O., Oettgen, H. F., Old, L. J., and Livingston, P. O., Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn, Cancer Res., 52, 5663, 1992.
76. Livingston, P. O., Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., Ritter, G., Oettgen, H. F., and Old, L. J., Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside, J. Clin. Oncol., 12, 1036, 1994.
77. Livingston, P. O., Adluri, S., Helling, F., Yao, T.-J., Kensil, C. R., Newman, M. J., and Marciani, D., Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet hemocyanin conjugate vaccine in patients with malignant melanoma, Vaccine, 12, 1275, 1994.
78. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers, J. Infect. Dis., 170, 1288, 1994.
79. M2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21, Cancer Res., 55, 2783, 1995.
80. Adluri, S., Helling, F., Ogata, S., Zhang, S. L., Itzkowitz, S. H., Lloyd, K. O., and Livingston, P. O., Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients, Cancer Immunol. Immunother., 41, 185, 1995.
81. Trauger, R. J., Ferre, F., Daigle, A. E., Jensen, F. C., Moss, R. B., Mueller, S. H., Richieri, S. P., Slade, H. B., and Carlo, D. J., Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogenon HIV-1 immunity, viral DNA, and percentage of CD4 cells, J. Infect. Dis., 169, 1256, 1994.
82. Turner, J. L., Trauger, R. J., Daigle, A. E., and Carlo, D. J., HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: Results of a double-blind, adjuvant-controlled, dose-ranging trial, AIDS, 8, 1429, 1994.
83. Moreland, L. W., Heck, L. W., Jr., Koopman, W. J., Saway, P. A., Adamson, T. C., Fronek, Z., O'Connor, R. D., Morgan, E. E., Diveley, J. P., Richieri, S. P., Carlo, D. J., and Brostoff, S. W., Vβ17 T cell receptor peptide vaccination in rheumatoid arthritis: Results of phase I dose escalation study, J. Rheumatol., 23, 1353, 1996.
84. Triozzi, P. L., Martin, E. W., Gochnour, D., and Aldrich, W., Phase Ib trial of a synthetic β human chorionic gonadotropin vaccine in patients with metastatic cancer, Ann. NY Acad. Sci., 690, 358, 1993.
85. Snyder, L. L., Woo, D. V., Triozzi, P. L., and Stevens, V. C., Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer, in Vaccine Design: The subunit and adjuvant approach, Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1995, 907.
86. Stevens, V. C., Cinader, B., Powell, J. E., Lee, A. C., and Koh, S. W., Preparation and formulation of a hCG antifertility vaccine: Selection of adjuvant and vehicle, Am. J. Repro. Immunol., 6, 315, 1981.
87. Stevens, V. C., Powell, J. E., Lee, A. C., and Griffin, D., Antifetility effects of immunization of female baboons with C-terminal peptides of the β-subunit of human chorionic gonadotropin, Fertil. Steril., 36, 98, 1981.
88. Moghimi, S. M., Hedeman, H., Christy, N. M., Illum, L., and Davis, S. S., Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats, J. Leukocyte Biol., 54, 513, 1993.
89. Moghimi, S. M. and Murray, J. C., Poloxamer-188 revisited: A potentially valuable immune modulator? J. Nat. Cancer Inst., 88, 766, 1996.
90. Cornbluth, J. W., Hart, P., Rees, R., and Stock, J., Antituberculosis effect of certain surface active polyoxethylene ethers in mice, Nature, 168, 150, 1951.
91. Cornbluth, J. W., Hart, P. D., Nicholls, G. A., Rees, R. J. W., and Stock, J. A., Antituberculosis effects of certain active polyoxyethylene ethers, Br. J. Pharmacol., 10, 73, 1955.
92. Cornbluth, J. W. and Hart, P. D., Mycobacterium tuberculosis in macrophages: Effect of certain surfactants and other membrane-active compounds, Science, 162, 686, 1968.
93. Hart, P. D. and Payne, S. N., Effects of non-ionic surfactants that modify experimental tuberculosis on lipase activity of macrophages, Br. J. Pharmacol., 43, 190, 1971.
94. Hart, P. D., Mycobacterium tuberculosis in macrophages: Effect of certain surfactants and other membrane-active compounds, Science, 162, 190, 1962.
95. Kondo, E. and Kanai, K., Triton WR-1339 as a biological response modifier in mycobacterial infection, Japanese J. Med. Sci. Biol., 139, 35, 1986.
96. Hunter, R. L., Jagannath, C., Tinkley, A., Behling, C. A., and Nolte, F., Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331, Antimicrob. Agents Chemother., 39, 435, 1995.
97. Jagannath, C., Allaudeen, H. S., and Hunter, R. L., Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo, Antimicrob. Agents Chemother., 39, 1349, 1995.
98. Krahenbuhl, J. L., Fukutomi, Y., and Gu, L., Treatment of acute experimental toxoplasmosis with investigational poloxamers, Antimicrob, Agents Chemother., 37, 2265, 1993.
99. Jagannath, C., Emanuele, M. R., and Hunter, R. L., Activity of poloxamer CRL1072 against drug sensitive and resistant strains of M tuberculosis in macropahges and in mice, Antimicrob. Agents Chemother, In Press, 1997.
100. Colbassani, H. J., Barrow, D. L., Sweeney, K. M., Bakay, R. A., Check, I. J., and Hunter, R. L., Modification of acute focal ischemia in rabbits by poloxamer 188, Stroke, 20, 1241, 1989.
101. Justicz, A. G., Farnsworth, W. V., Soberman, M. S., Tuvlin, M. B., Bonner, G. D., Hunter, R. L., Martino, S. D., Sink, J. D., and Austin, G. E., Reduction of muocardial infarct size by poloxamer 188 and mannitol in a canine model, Am. Heart J., 122, 671, 1991.
102. Mayer, D. C., Strada, S. J., Hoff, C., Hunter, R. L., and Artman, M., Effects of poloxamer 188 in a rabbit model of hemorrhagic shock, Ann. Clin. Lab. Sci., 24, 302, 1994.
103. Smith, C. M., Hebbel, R. P., Tukey, D. P., Clawson, C. C., White, J. G., and Vercellotti, G. M., Pluronic F68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes, Blood, 69, 1631, 1987.
104. Ketchum, L. D., Wennen, W. W., Masters, F. W., and Robinson, D. W., Experimental use of pluronic F68 in microvascualr surgery, Plastic Reconstruc. Surgery, 53, 288, 1974.
105. Hymes, A. C., Safavian, M. H., and Gunther, T., The influence of an industrial surfactant Pluronic 68, in the treatment of hemorrhagic shock, J. Surg. Res., 11, 191, 1971.
106. Millet, P., Kalish, M., Collins, W. E., and Hunter, R. L., Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malarial peptide vaccine, Vaccine, 10, 547, 1992.
107. Elson, C. O., Tomasi, M., Dertzbaugh, M., Thaggard, G., Hunter, R. L., and Weaver, G., Oral-antigen delivery by way of a multiple emulsion system enhances oral tolerance, Ann. NY Acad. Sci. 778, 156, 1996.
108. Miller, A., Lider, O., Roberts, A. B., Sporn, M., and Weiner, H. L., Suppressor T cells generated by oral tolerization to myelin basic protein suppresses both in vitro and in vivo immune responses by the release of TGF-β following antigen-specific triggering, Proc. Natl. Acad. Sci. USA, 89, 421, 1992.
109. Husby, S., Mestecky, J., Moldoveanu, Z., Holland, S., and Elson, C. O., Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding, J. Immunol., 152, 4663, 1994.
110. + cells mediate active suppression, J. Immunol., 155, 910, 1995.
111. Weiner, H. L., Mackin, G. A., Matsui, M., Orav, E. J., Khoury, S. J., Dawson, D. M., and Hafler, D. A., Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis, Science, 259, 1321, 1993.
112. Trentham, D. E., Dynesius-Trentham, R. A., Orav, E. J., Combitchi, D., Lorenzo, C., Sewell, K. L., Hafler, D. A., and Weiner, H. L., Effects of oral administration of type II collagen on rheumatoid arthritis, Science, 261, 1727, 1993.
113. Weiner, H. L., Miller, A., Khoury, S. J., Zhang, Z. J., Al-Sabbagh, A., Brod, S. A., Lider, O., Higgins, P., Sobel, R., Matsui, M., Sayegh, M., Carpenter, C., Eisenbarth, G., Nussenblatt, R. B., and Hafler, D. A., Treatment of autoimmune diseases by oral tolerance to autoantigens, Adv. Exp. Med. Biol., 371B PT 2, 1217, 1995.
114. Weiner, H. L., Friedinan, A., Miller, A., Khoury, S. J., Al-Sabbagh, A., Santos. L., Sayegh, M., Nussenblatt, R. B., Trentham, D. E., and Hafler,D. A., Oral tolerance: Immunolgoical mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens, Annu. Rev. Immunol., 12, 809, 1994.
115. Cooper, P. D., Solid phase activators of the alternative pathway of complement, in Activators and Inhibitors of Complement, Sim, R. M., Ed., Dordrecht: Kluwer Academic Publishers, 1993, 69.
116. + cytotoxic T lymphocyte responses, J. Immunol., 148, 2357, 1992.
117. Lichtenfels, R., Biddison, W. E., Schulz, H., Vogt, A. B., and Martin, R., CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity, J. Immunol. Methods, 172, 227, 1994.
118. Sewell, D. L., Rashad, A. L., Rourke, W. J. J., Poor, S. L., McCarthy, J. A., and Pfaller, M. A., Comparison of the Septi-Check AFB and BACTEC systems and conventional culture for recovery of mycobacteria, J. Clin. Microbiol., 31, 2689, 1993.
119. Todd, C. W., Pozzi, L.-A. M., Gurnaccia, J. R., Balasubramanian, M., Henk, W. G., Younger, L. E., and Newman, M. J., Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccine formulations, Vaccine, 15, 564, 1997.